The abstract is read at the publisher; the summary is JClub's.
Restoring interleukin-17D (IL-17D) in orthotopic glioblastoma models substantially extends survival by selectively reprogramming the myeloid compartment.
- Why it matters: Glioblastoma creates an immunosuppressive microenvironment that limits immunotherapy, but how CNS cytokine homeostasis signals are subverted during gliomagenesis is unclear.
- What they did: IL-17D is downregulated during gliomagenesis and, when restored, engages CD93 to assemble a SCARB1-containing costimulatory receptor complex in lipid rafts, activating Fyn/BCAP and PI3K/AKT/NF-κB signaling.
- The result: This reprogramming inverts SCARB1’s function from tolerogenic efferocytosis to active antigen presentation, reshaping the GBM immune landscape and supporting IL-17D as a therapeutic target.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.